DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for metatropic dysplasia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMetatropic dysplasia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for metatropic dysplasia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transient receptor potential cation channel subfamily V member 4 (TRPV4) — TRPV4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8T1E · 2.77 Å · ligand [(2~{R})-2-[(~{Z})-hexadec-9-enoyl]oxy-3-[oxidanyl-[2-(trimethyl-$l^{4}-azanyl)ethoxy]phosphoryl]oxy-propyl] (~{Z})-docos-13-enoate (9ZR). Experimental structure, not a prediction.
What the evidence adds up to
Metatropic dysplasia accounts for approximately 5% of cases recorded by the International Skeletal Dysplasia Registry, with a single recorded lethal case. Four forms are recognised: type I, lethal autosomal recessive; type II, nonlethal autosomal recessive with survival to childhood; type III, autosomal dominant with typical features; and type IV, a mild form with uncertain inheritance. A 1998 case report of type I disease described a persistent tail, unique lung dysmorphology, and thyroidal agenesis. The literature contains few well-documented histopathologic reports.
The condition is an autosomal dominant skeletal disorder caused by pathogenic variants in the TRPV4 gene, which encodes a non-selective calcium channel involved in bone homeostasis. A 2025 case series reported three patients, all exhibiting a bell-shaped thorax, significant platyspondyly, and shortened long bones with broad metaphyses. Patients 1 and 3 had more complex clinical courses including seizures and global developmental delay. Genetic analysis revealed two different TRPV4 variants: p.Asn796del in patient 1 and p.Pro799Leu in patients 2 and 3. The co-occurrence of neurological symptoms and skeletal abnormalities in these patients suggests a clinically heterogeneous spectrum consistent with a single disease rather than distinct entities.
No drug treatment, repurposed or otherwise, is mentioned in any of these abstracts. No clinical trial data, response rates, or survival statistics beyond the registry prevalence figure are provided. The 2025 paper calls for a comprehensive, multidisciplinary approach to management but offers no pharmacological intervention.
What is missing is any preclinical or clinical investigation of drug candidates, any systematic trial design, any patient stratification strategy, and any funding directed at therapeutic development for metatropic dysplasia.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric and Developmental Pathology · 1998 · 10 citations · open access
Morphologic Observations in a Case of Lethal Variant (Type I) Metatropic Dysplasia with Atypical Features: Morphology of Lethal Metatropic Dysplasia
AbstractMetatropic dysplasia accounts for approximately 5% of cases recorded by the International Skeletal Dysplasia Registry, with a single recorded lethal case. Four forms of the disease are currently recognized: type I, lethal autosomal recessive form; type II, nonlethal autosomal recessive form with survival to childhood; type III, autosomal dominant form with typical features, and type IV, a mild form with uncertain inheritance. The literature contains few well-documented reports of the histopathologic findings in metatropic dysplasia. In this report, we present the radiologic and histopathologic features in a cas e of type I metatropic dysplasia, with the unusual features of a persist ent tail, unique lung dysmorphology, and thyroidal agenesis.
Pediatric and Developmental Pathology · 1998 · 10 citations
CASE REPORTS: Morphologic Observations in a Case of Lethal Variant (Type I) Metatropic Dysplasia with Atypical Features: Morphology of Lethal Metatropic Dysplasia
AbstractMetatropic dysplasia accounts for approximately 5% of cases recorded by the International Skeletal Dysplasia Registry, with a single recorded lethal case. Four forms of the disease are currently recognized: type I, lethal autosomal recessive form; type II, nonlethal autosomal recessive form with survival to childhood; type III, autosomal dominant form with typical features, and type IV, a mild form with uncertain inheritance. The literature contains few well-documented reports of the histopathologic findings in metatropic dysplasia. In this report, we present the radiologic and histopathologic features in a cas e of type I metatropic dysplasia, with the unusual features of a persist ent tail, unique lung dysmorphology, and thyroidal agenesis.
International Journal of Molecular Sciences · 2025 · 0 citations · open access
The Broad Clinical Spectrum of Metatropic Dysplasia: A Case Series and Literature Review
AbstractMetatropic dysplasia is an autosomal dominant skeletal disorder characterized by progressive kyphoscoliosis, severe platyspondyly, pronounced metaphyseal enlargement, and shortening of the long bones. This condition is caused by pathogenic variants in the TRPV4 (Transient Receptor Potential Vanilloid 4) gene, which encodes a non-selective calcium channel involved in bone homeostasis. Variants in TRPV4 have been associated with two major disease groups: skeletal dysplasias and neuropathies, with recent findings indicating an overlap in their clinical features. We report three patients with metatropic dysplasia, each presenting a distinct severity profile. All exhibited a bell-shaped thorax, significant platyspondyly, and shortened long bones with broad metaphyses. Notably, patients 1 and 3 had more complex clinical courses, including seizures and global developmental delay. Genetic analysis revealed two different TRPV4 variants: p.Asn796del (patient 1) and p.Pro799Leu (patients 2 and 3). These cases illustrate variability in extra-skeletal manifestations, complications, and prognosis. In our patients with TRPV4-related disorders, the co-occurrence of neurological symptoms and skeletal abnormalities suggests a clinically heterogeneous spectrum consistent with a single disease rather than distinct entities. A comprehensive, multidisciplinary approach is essential to optimize management and improve the quality of life for patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
